||||||||||LG00034053 / LG Chem Trial completion, Trial completion date, Trial primary completion date: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA (clinicaltrials.gov) - May 3, 2024 P1/2, N=74, Completed, Sponsor: LG Chem Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Mar 2024 --> Dec 2023
||||||||||LG00034053 / LG Chem Enrollment closed, Enrollment change: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA (clinicaltrials.gov) - Feb 9, 2024 P1/2, N=74, Active, not recruiting, Sponsor: LG Chem Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Mar 2024 --> Dec 2023 Recruiting --> Active, not recruiting | N=135 --> 74
||||||||||LG00034053 / LG Chem Trial completion date, Trial primary completion date: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA (clinicaltrials.gov) - Mar 9, 2023 P1/2, N=135, Recruiting, Sponsor: LG Chem Recruiting --> Active, not recruiting | N=135 --> 74 Trial completion date: Dec 2023 --> Nov 2024 | Trial primary completion date: Dec 2022 --> Mar 2024